{"id":"https://openalex.org/W2574834352","doi":"https://doi.org/10.1182/blood.v112.11.252.252","title":"Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma","display_name":"Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma","publication_year":2008,"publication_date":"2008-11-16","ids":{"openalex":"https://openalex.org/W2574834352","doi":"https://doi.org/10.1182/blood.v112.11.252.252","mag":"2574834352"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v112.11.252.252","doi":"https://doi.org/10.1182/blood.v112.11.252.252","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.252.252","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026496212","display_name":"Richard J. Rickles","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard J Rickles","raw_affiliation_strings":["CombinatoRx, Incorporated, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Incorporated, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112244663","display_name":"Laura T. Pierce","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laura Pierce","raw_affiliation_strings":["CombinatoRx, Incorporated, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Incorporated, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Thomas Giordano","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas Giordano","raw_affiliation_strings":["CombinatoRx, Incorporated, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Incorporated, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080011913","display_name":"William Avery","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Avery","raw_affiliation_strings":["CombinatoRx, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Inc., Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074988630","display_name":"Melissa Farwell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melissa Farwell","raw_affiliation_strings":["CombinatoRx, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Inc., Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074206584","display_name":"DAVID F. CROWE","orcid":"https://orcid.org/0000-0002-5393-9770","observed_orcids":["https://orcid.org/0000-0002-5393-9770"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Crowe","raw_affiliation_strings":["CombinatoRx, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Inc., Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058589851","display_name":"Winnie F. Tam","orcid":"https://orcid.org/0000-0001-9978-3428","observed_orcids":["https://orcid.org/0000-0001-9978-3428"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Winnie F. Tam","raw_affiliation_strings":["CombinatoRx, Incorporated, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Incorporated, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100360828","display_name":"Mei Chen","orcid":"https://orcid.org/0000-0001-5661-1386","observed_orcids":["https://orcid.org/0000-0001-5661-1386"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mei Chen","raw_affiliation_strings":["CombinatoRx, Incorporated, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Incorporated, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015250372","display_name":"Vikram V. Kansra","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vikram Kansra","raw_affiliation_strings":["CombinatoRx, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Inc., Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115591881","display_name":"Douglas W. McMillin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas W. McMillin","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C Anderson","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine Mitsiades","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":null,"display_name":"Margaret S. Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Margaret S. Lee","raw_affiliation_strings":["CombinatoRx, Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CombinatoRx, Inc., Cambridge, MA, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.38114369,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":95},"biblio":{"volume":"112","issue":"11","first_page":"252","last_page":"252"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9038000106811523,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9038000106811523,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.07339999824762344,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.007600000128149986,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adenosine-a2a-receptor-agonist","display_name":"adenosine A2A receptor agonist","score":0.9739999771118164},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.996999979019165},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.8510000109672546},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7929999828338623},{"id":"https://openalex.org/keywords/dexamethasone-resistance","display_name":"dexamethasone resistance","score":0.8709999918937683},{"id":"https://openalex.org/keywords/lenalidomide-resistance","display_name":"lenalidomide resistance","score":0.9869999885559082},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9549999833106995},{"id":"https://openalex.org/keywords/glucocorticoids","display_name":"glucocorticoids","score":0.7590000033378601},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.7799999713897705},{"id":"https://openalex.org/keywords/hsp90-inhibitors","display_name":"Hsp90 inhibitors","score":0.9909999966621399},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.7210000157356262},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.7670000195503235},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.6140000224113464}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6852385997772217},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6441682577133179},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.6230626702308655},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.601911187171936},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5772547125816345},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.5577946901321411},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.4571083188056946},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.45616939663887024},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.4485020041465759},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.42682313919067383},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.4129568934440613},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3389221429824829},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.326604425907135},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.25614142417907715},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.24056583642959595},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2192196249961853},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.188848614692688},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.16790145635604858},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v112.11.252.252","doi":"https://doi.org/10.1182/blood.v112.11.252.252","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.252.252","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2577976253","https://openalex.org/W2573791292","https://openalex.org/W2557938957","https://openalex.org/W2546020874","https://openalex.org/W2592107223","https://openalex.org/W2095373531","https://openalex.org/W2163564388","https://openalex.org/W7100705173","https://openalex.org/W2979840774","https://openalex.org/W2558236138"],"abstract_inverted_index":{"Abstract":[0],"We":[1],"have":[2],"made":[3],"the":[4,25,80,197,219,289,294,350,387,396,469,504,524,537],"surprising":[5],"discovery":[6],"that":[7,37,412],"agonism":[8],"of":[9,28,50,58,77,140,159,171,204,209,231,237,259,266,291,296,346,375,391,398,410,433,440,446,471,507,526,536,540,548],"adenosine":[10,33],"A2A":[11,34,514],"receptors":[12],"has":[13],"potent":[14,31,54,510],"and":[15,70,99,104,115,124,149,178,200,268,306,337,372,389,402,477,511],"synergistic":[16,235,373,437,513,520],"antiproliferative":[17,357,438],"effects":[18,72,358,439],"in":[19,44,47,60,79,120,136,168,191,196,212,244,250,255,284,288,293,314,352,365,395,415,419,428,463,534,544],"B-cell":[20,304],"malignancies.":[21],"Here":[22],"we":[23,502],"describe":[24],"preclinical":[26,505,529],"evaluation":[27,506],"CRx-501,":[29,508],"a":[30,137,192,201,251,271,285,370,422,429,460,488,509,517],"selective":[32,302],"receptor":[35],"agonist":[36,515],"synergizes":[38,95],"with":[39,64,96,133,181,246,281,363,367,421,448,468,495],"established":[40],"anti-MM":[41],"agents":[42],"resulting":[43,283,427],"enhanced":[45,394],"efficacy":[46,260,390],"pre-clinical":[48],"models":[49,445],"MM.":[51,527,549],"CRx-501":[52,87,134,162,183,232,248,299,364,392,411,441,478,541],"demonstrates":[53,88,307],"single":[55,89,309,383],"agent":[56,90,310,384],"inhibition":[57,76,170,180,236,265],"proliferation":[59,78,172,238,267],"MM":[61,82,142,153,353,447],"cell":[62,83,143,274,318,340,354],"lines":[63,84,144,341],"EC50s":[65],"ranging":[66,73],"from":[67,74,261],"2\u201320":[68],"nM":[69,161,165],"maximum":[71],"20\u201375%":[75],"10":[81,141,193,399],"surveyed.":[85],"While":[86],"effects,":[91],"this":[92],"molecule":[93],"potently":[94],"glucocorticoids":[97],"(dexamethasone":[98],"prednisolone),":[100],"bortezomib,":[101],"lenalidomide,":[102,247],"melphalan":[103],"doxorubicin":[105],"as":[106,108,173,379,516],"well":[107],"emerging":[109],"drug":[110,521],"classes":[111],"including":[112,145,320],"HDAC":[113],"inhibitors":[114],"HSP90":[116],"inhibitors.":[117],"Substantial":[118],"increases":[119],"overall":[121],"effect":[122],"levels":[123,208],"2":[125],"to":[126,151,163,175,215,218,263,381,487],"100":[127,164],"fold":[128,194,253],"potency":[129,388],"shifts":[130],"are":[131,413,417],"observed":[132,280],"combinations":[135],"broad":[138],"panel":[139],"those":[146],"both":[147],"sensitive":[148],"resistant":[150,214,273],"current":[152],"agents.":[154],"In":[155,500],"MM.1S":[156],"cells,":[157,324,328,332],"addition":[158,230],"50":[160],"Dexamethasone":[166],"results":[167,190,249],"95%":[169],"compared":[174,380,486],"approximately":[176],"60":[177],"75%":[179],"either":[182,382,496],"or":[184,312,490],"dexamethasone":[185,198,216,368,472,498],"alone":[186],"respectively.":[187,499],"This":[188],"combination":[189,202,245,366,470,546],"shift":[195,254,287],"IC50":[199,290,351],"index":[203],"0.2":[205],"indicating":[206],"high":[207],"synergy.":[210],"Importantly,":[211,298],"cells":[213,336],"up":[217],"highest":[220],"concentrations":[221,343],"tested":[222],"(2":[223],"microM;":[224],"EJM,":[225],"ANBL-6,":[226],"MM.1R,":[227],"KSM-12PE,":[228],"MOLP-8),":[229],"can":[233],"induce":[234],"converting":[239],"resistance":[240],"into":[241,443],"sensitivity.":[242],"Similarly,":[243],">50":[252],"IC50,":[256],"an":[257],"enhancement":[258],"50%":[262],"90%":[264],"activity":[269,311],"against":[270],"lenolidamide":[272],"line":[275],"(MOLP-8).":[276],"Synergy":[277],"is":[278,300,393],"also":[279],"bortezomib":[282,292],"2-fold":[286],"presence":[295,397],"CRx-501.":[297],"highly":[301,512],"for":[303,483,523,542],"malignancies":[305],"no":[308,449],"synergy":[313],"normal":[315],"primary":[316],"human":[317,404],"types":[319],"peripheral":[321],"blood":[322],"mononuclear":[323],"umbilical":[325],"vein":[326],"endothelial":[327,335],"aortic":[329],"smooth":[330],"muscle":[331],"coronary":[333],"artery":[334],"solid":[338],"tumor":[339,464],"at":[342],"2\u20133":[344],"orders":[345],"magnitude":[347],"greater":[348],"than":[349],"lines.":[355],"These":[356],"occur":[359],"through":[360],"apoptosis.":[361],"Treatment":[362],"causes":[369],"rapid":[371],"induction":[374],"Annexin":[376],"V":[377],"expression":[378],"alone.":[385],"Surprisingly,":[386],"ng/mL":[400],"interleukin-6":[401],"HS-5":[403],"bone":[405],"marrow":[406],"stromal":[407],"cells.":[408],"Concentrations":[409],"effective":[414],"vitro":[416],"achievable":[418],"mice":[420],"3":[423],"mg/kg":[424,480],"s.c.":[425,481],"dose":[426],"mean":[430],"plasma":[431],"AUC0\u201324":[432],"1228":[434],"ng*hr/mL.":[435],"The":[436],"translate":[442],"xenograft":[444],"significant":[450],"body":[451],"weight":[452],"loss.":[453],"Mice":[454],"bearing":[455],"subcutaneous":[456],"H929":[457],"tumors":[458],"show":[459],"73%":[461],"reduction":[462],"volume":[465],"after":[466,493],"treatment":[467,494,525],"(1":[473],"mg/kg,":[474],"s.c":[475],"QD)":[476,482],"(3":[479],"34":[484],"days":[485],"36%":[489],"37%":[491],"decrease":[492],"CRx-501or":[497],"summary,":[501],"report":[503],"novel,":[518],"selective,":[519],"candidate":[522],"Our":[528],"data":[530],"provides":[531],"compelling":[532],"evidence":[533],"support":[535],"further":[538],"development":[539],"use":[543],"multi-drug":[545],"therapy":[547]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-01-26T00:00:00"}